Navigation Links
Escalon(R) Reports Financial Results for 2007 Fiscal Year
Date:9/28/2007

$3,461,322 $2,828,196

Total costs and

expenses $8,793,590 $8,284,674 $33,038,975 $32,826,888

(Loss) income from

operations $(1,319,470) $(1,076,894) $5,798,805 $(3,036,190)

Other income and

(expense):

Gain on sale of

available for sale

securities $75,000 $- $75,000 $1,157,336

Equity in Ocular

Telehealth

Management, LLC $(31,963) $(103,872) $(87,852) $(173,844)

Interest income $95,072 $49,890 $208,457 $161,588

Interest expense $(5,138) $(16,100) $(28,753) $(63,521)

Total other income

and (expense) $132,971 $(70,082) $166,852 $1,081,559

Net (loss) income

before taxes $(1,186,499) $(1,146,976) $5,965,657 $(1,954,631)

Provision for income

taxes $(13,860) $(4,715) $51,054 $31,309

Net (loss) income $(1,172,639) $(1,142,261) $5,914,603 $(1,985,940)

Basic net (loss)

income per share $(0.18) $(0.19) $0.93 $(0.32)

Diluted net (loss)

income per share $(0.18) $(0.19) $0.92 $(0.32)

Weighted average

shares - basic 6,374,929 6,152,455 6,374,929 6,152,455

Weighted average

shares - diluted 6,434,275 6,152,455 6,434,275 6,152,455

SELECTED BALANCE SHEET DATA:

June 30, June 30,

2007 2006

Cash, cash equivalents and Investments $8,879,462 $3,429,930

Total current assets $21,763,012 $14,911,249

Total assets $45,017,213 $38,644,767

Current liabilities
'/>"/>

SOURCE Escalon Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:Procter & Gamble Announces Appointment of Director 2Health News:Possible ovarian cancer treatment target identified 2Health News:Testosterone Gets Bad Rap: Study 2Health News:Testosterone Gets Bad Rap: Study 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 2Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 4Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 5Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 6Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 7Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 8Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 9Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 10Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 11Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 12Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 13Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 14Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 15Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 16Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 17Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 18Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 19Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 20Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 21
Breaking Medicine Technology:Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Members of National CHD Organization Unite for Little Hearts Celebration and Assemble for Picture of Hope 48154 1Members of National CHD Organization Unite for Little Hearts Celebration and Assemble for Picture of Hope 48154 2Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 1Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 2Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 3Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 4Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 5Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 1Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 2Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 3Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 4